Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Polycystic Ovary Syndrome 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Radiosurgery 50Magnetic Resonance Spectroscopy 34Temozolomide 28Bevacizumab 24pembrolizumab 23Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7Blood Specimen Collection 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Lomustine 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Capsules × 1 year × Clear all
NCT03753685 2025-07-23

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Fudan University

Phase 2 Active not recruiting
27 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡